<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Contrast-associated and contrast-induced acute kidney injury: Clinical features, diagnosis, and management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael R Rudnick, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul M Palevsky, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John P Forman, MD, MSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) may develop after administration of iodinated contrast material. AKI that is related to iodinated contrast material has historically been called contrast-induced nephropathy (CIN) or contrast-induced AKI (CI-AKI). However, nephrology and radiology communities have also adopted the term "contrast-associated AKI (CA-AKI)," because it is not possible to exclude other causes of AKI in many clinical and most research settings. CA-AKI is a generally reversible form of AKI, although its development may be associated with adverse outcomes [<a href="#rid1">1-11</a>]. (See  <a class="medical medical_review" href="/z/d/html/7225.html" rel="external">"Kidney and patient outcomes after acute kidney injury in adults"</a>.)</p><p>This topic reviews the pathogenesis, clinical characteristics, and diagnosis of iodinated CI-AKI. Preventive strategies for reducing the risk of CI-AKI and a discussion of acute tubular necrosis (ATN), the most common cause of AKI developing in hospitalized patients, are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults"</a>.)</p><p></p><p class="headingAnchor" id="H1201588825"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Acute kidney injury (AKI) that occurs shortly after administration of iodinated contrast may or may not be causally related to contrast material:</p><p class="bulletIndent1"><span class="glyph">●</span>"Contrast-associated AKI (CA-AKI)" or, synonymously, "postcontrast AKI" are broad terms that refer to AKI occurring shortly after administration of iodinated contrast and that may or may not be directly caused by the contrast material. The term CA-AKI applies to situations in which a detailed clinical evaluation for other potential AKI etiologies has not been performed or in which other causes of AKI cannot be reasonably excluded. CA-AKI should also be used to refer to increases in creatinine (or decreases in estimated glomerular filtration rate [eGFR]) after contrast exposure in research studies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>"Contrast-induced AKI (CI-AKI)," previously called "contrast-induced nephropathy (CIN)," is a specific term that refers to the subset of postcontrast AKI that is judged to be causally linked to contrast material administration. In an individual patient, the presence of a causal link between contrast exposure and AKI can only be judged after a thorough clinical evaluation for other potential causes of AKI. If after such an evaluation, no other causes (other than contrast exposure) are identified, then it is appropriate in these instances to use the term CI-AKI. Although some experts contend that, even after a thorough clinical evaluation fails to reveal an alternative etiology, it is not possible to establish causality. However, this is also the case for other causes of AKI, such as sepsis-induced acute tubular necrosis (ATN), or ATN caused by an alternative nephrotoxic agent.</p><p></p><p>Intravascular iodinated contrast media have been considered nephrotoxic based in large part upon animal experiments, uncontrolled human studies, and anecdotal observations [<a href="#rid12">12,13</a>]. (See <a class="local">'Pathogenesis'</a> below.)</p><p>However, because many of these older reports lacked comparable control groups that did not receive contrast material, their applicability to our understanding of CI-AKI is unclear. Large propensity-matched controlled studies have since suggested that many cases of AKI following contrast administration may in fact be related to coincident nephrotoxic exposures (eg, hypovolemia, cardiac dysfunction, infection) present at the time that contrast material was administered [<a href="#rid13">13-24</a>].</p><p>As a result of these larger studies, multiple authorities in the radiology and nephrology communities adopted alternate terms (CA-AKI or postcontrast AKI) to refer to any AKI that occurs shortly after administration of iodinated contrast material [<a href="#rid25">25,26</a>]. Such terms are agnostic to cause and include both CI-AKI as well as coincidental AKI. Since coincident AKI is so common, true CI-AKI cannot be diagnosed accurately in the context of a clinical research study, even when conducted with a control arm not exposed to contrast material [<a href="#rid12">12-23,26</a>].</p><p>Thus, the term "CI-AKI" (or "CIN") should be reserved for AKI that can be causally linked to contrast material administration. If other potential etiologies have not been excluded or if other potential etiologies are identified, then AKI occurring shortly after contrast exposure should be referred to as "CA-AKI" or "postcontrast AKI."</p><p class="headingAnchor" id="H3"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The best data related to the nephrotoxicity of contrast media come from animal models. Studies show evidence of acute tubular necrosis (ATN), but the mechanism by which ATN occurs is not well understood [<a href="#rid27">27-29</a>]. The two major theories are that ATN is caused by renal vasoconstriction resulting in medullary hypoxia, possibly mediated by effects of viscosity and by alterations in nitric oxide, endothelin, and/or adenosine, and also as a direct result of the cytotoxic effects of the contrast agents on tubular cells [<a href="#rid27">27-35</a>]. Tubular cell injury may be exacerbated by renal vasoconstriction [<a href="#rid27">27,28,33,36</a>], and these two theories are not mutually exclusive.</p><p>Compared with other types of ATN (such as ischemic), contrast-induced acute kidney injury (CI-AKI) is usually characterized by relatively rapid recovery of kidney function (see <a class="local">'Clinical features'</a> below). If ATN contributes to CI-AKI, it is not clear why recovery occurs relatively quickly (ie, within a few days) compared with a longer duration (ie, one to three weeks), as with ATN due to other causes. One likely possibility is that the degree of tubular necrosis is much less severe than seen in other settings. It is also possible that the decline in glomerular filtration rate (GFR) is due to functional changes in tubule epithelial cells rather than necrosis. This phenomenon may be at least in part due to redistribution of membrane transport proteins from the basolateral to the luminal membrane [<a href="#rid37">37</a>].</p><p>In addition, it is possible that prerenal factors or intratubular obstruction contribute to the pathogenesis. This possibility is suggested by the observation that the fractional sodium excretion (FENa) may be &lt;1 percent in patients with CI-AKI, which is characteristic of prerenal physiology [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/7219.html" rel="external">"Fractional excretion of sodium, urea, and other molecules in acute kidney injury", section on 'Fractional excretion of sodium in acute kidney injury'</a> and <a class="local">'Clinical features'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The major clinical manifestations of contrast-induced acute kidney injury (CI-AKI) include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Early, mild increase in serum creatinine</strong> – An increase in serum creatinine that is generally observed within 24 to 48 hours after the iodinated contrast exposure and that is usually mild. The serum creatinine typically starts to decline toward baseline within three to seven days of the exposure to contrast [<a href="#rid8">8,39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonoliguria</strong> – Because the AKI is typically mild, most patients are nonoliguric [<a href="#rid4">4,39</a>]. Oliguria (if it occurs) develops immediately after the procedure. Oliguria and more significant elevations in creatinine can be seen with severe AKI or when CI-AKI develops in patients with moderate to severe chronic kidney disease (CKD) at baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urinary sediment consistent with acute tubular necrosis</strong> – The urinary sediment may show classic findings of acute tubular necrosis (ATN), including muddy brown granular and epithelial cell casts and free renal tubular epithelial cells (<a class="graphic graphic_picture graphicRef56438" href="/z/d/graphic/56438.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef86348" href="/z/d/graphic/86348.html" rel="external">picture 2</a>). However, the absence of these urinary findings does not exclude the possibility of CA-AKI.</p><p></p><p>Other manifestations of reduced glomerular filtration rate (GFR) may be present, including hyperkalemia, acidosis, and hyperphosphatemia. (See  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H3939612998"><span class="h1">EVALUATION</span><span class="headingEndMark"> — </span>Patients who have suspected contrast-induced acute kidney injury (CI-AKI) should undergo a focused history and physical examination (to elucidate other possible causes of AKI) and have a urinalysis with microscopic examination of the urinary sediment (to identify findings consistent with a diagnosis of CI-AKI or findings that suggest an alternative etiology). Oliguria and severe AKI are less common findings in CI-AKI. Thus, patients with oliguria and patients with severe AKI (who may require kidney replacement therapy) should undergo a more extensive evaluation for alternate etiologies of AKI.</p><p>Although an ultrasound is often obtained among hospitalized patients with AKI, we generally do not obtain an ultrasound initially among patients whose presentation is characteristic of CI-AKI. However, we do obtain an ultrasound to exclude other causes of AKI among patients with risk factors for urinary tract obstruction who do not follow a classic clinical course of CI-AKI or if the diagnosis of CA-AKI is questionable (eg, oliguria, severe AKI). (See  <a class="medical medical_review" href="/z/d/html/7188.html" rel="external">"Diagnostic approach to adult patients with subacute kidney injury in an outpatient setting"</a>.)</p><p>The urinalysis provides important diagnostic information by excluding other causes of AKI. However, it does not provide a conclusive, positive diagnosis of CI-AKI. As noted above, the classic findings of CI-AKI, including muddy brown granular and epithelial cell casts and free renal tubular epithelial cells, are not present in all patients diagnosed with CI-AKI and are not specific for CI-AKI. (See <a class="local">'Clinical features'</a> above and  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults", section on 'Urinalysis'</a> and  <a class="medical medical_review" href="/z/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease", section on 'Examination of the urine sediment'</a>.)</p><p>However, the absence of other findings, such as white blood cells (WBCs), WBC casts, dysmorphic red blood cells (RBCs), and RBC casts, is useful to exclude interstitial nephritis and glomerular diseases as causes of AKI. Conversely, the presence of WBCs, WBC casts, dysmorphic RBCs, or RBC casts suggests causes of AKI other than acute tubular necrosis (ATN), such as interstitial nephritis or glomerular lesions. Such patients often require a kidney biopsy.</p><p>Protein excretion in patients with CI-AKI is typically absent or mild (unless the patient had proteinuric chronic kidney disease [CKD] at baseline). However, the presence of albuminuria (detected by a qualitative dipstick or by an albumin-to-creatinine ratio) does <strong>not</strong> exclude CI-AKI, even if albuminuria was not previously present; the reasons for this are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Many of the commonly used iodinated radiocontrast agents induce false-positive results when either a dipstick or sulfosalicylic acid is used to detect proteinuria [<a href="#rid40">40</a>]. How this occurs is not clear, but protein excretion may be overestimated by as much as 1.5 to 2 g/L. Thus, the dipstick may be positive for albuminuria within the first 24 hours of contrast administration, even if albumin excretion is truly normal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An albumin-to-creatinine ratio may reveal moderately or severely increased albuminuria in the acute phase of AKI (regardless of the cause) due to a low urine creatinine combined with impaired tubular reabsorption of albumin [<a href="#rid41">41</a>].</p><p></p><p>There are no characteristic radiographic features of contrast nephropathy. As in other causes of AKI, a prolonged nephrogram may be seen among patients with CI-AKI who undergo a noncontrast-enhanced computed tomography (CT) scan [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Contrast-induced acute kidney injury (CI-AKI) is a clinical diagnosis. A clinical diagnosis of CI-AKI is made based upon the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>The characteristic rise in serum creatinine concentration beginning within the first 24 to 48 hours after contrast exposure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the judgment of the clinician, reasonable exclusion of other causes of AKI.</p><p></p><p class="bulletIndent1">As noted above, exclusion of other causes of AKI requires a routine evaluation of AKI with careful history and physical, urinalysis, and other pertinent laboratory studies; kidney ultrasound and kidney biopsy may be needed, if appropriate. (See <a class="local">'Evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/102834.html" rel="external">"Evaluation of acute kidney injury among hospitalized adult patients"</a>.)</p><p></p><p class="bulletIndent1">Even if other causes of AKI are identified, it is still possible that iodinated contrast exposure may have contributed to kidney injury.</p><p></p><p>A kidney biopsy is generally not helpful for the diagnosis of CI-AKI, since the lesions of ATN are focal and nonspecific and because CI-AKI is generally short lived. However, as with the ultrasound, a biopsy may rarely be required to exclude other causes of AKI among patients who do not follow a classic clinical course or in whom the diagnosis of contrast nephropathy is uncertain.</p><p class="headingAnchor" id="H454598616"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis includes, but is not limited to, renal atheroemboli (in setting of intra-arterial contrast administration), ischemic acute tubular necrosis (ATN), acute interstitial nephritis, and prerenal changes caused by the addition of or dose adjustments in diuretics and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in the postcontrast period. (See  <a class="medical medical_review" href="/z/d/html/7216.html" rel="external">"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7234.html" rel="external">"Clinical manifestations and diagnosis of acute interstitial nephritis"</a>.)</p><p>Among patients who develop AKI after angiography, CI-AKI must be distinguished from renal atheroemboli. Renal atheroemboli are generally characterized by one or more of the following [<a href="#rid8">8</a>] (see  <a class="medical medical_review" href="/z/d/html/7182.html" rel="external">"Clinical presentation, evaluation, and treatment of renal atheroemboli"</a> and  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of other embolic lesions (such as digital ischemia of the toes) or livedo reticularis (<a class="graphic graphic_picture graphicRef58761" href="/z/d/graphic/58761.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef79545" href="/z/d/graphic/79545.html" rel="external">picture 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Transient eosinophilia and hypocomplementemia, although these findings are not observed in all patients with renal atheroemboli</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed onset of kidney function decline, often days to weeks after angiography (whereas contrast-associated AKI [CA-AKI] develops within 48 hours of angiography)</p><p class="bulletIndent1"><span class="glyph">●</span>Protracted course with frequently little or no recovery of kidney function</p><p></p><p class="headingAnchor" id="H18300539"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The management of patients with contrast-associated acute kidney injury (CA-AKI) is supportive and includes elimination and avoidance of other potential kidney insults, hemodynamic and electrolyte assessment and management, appropriate dose adjustment of medications for the reduction in glomerular filtration rate (GFR), and, among those with severely decreased kidney function, monitoring for uremic signs and symptoms. An overview of the management of AKI is presented separately. (See  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>.)</p><p>A variety of interventions have been used to prevent the development of CI-AKI. Prevention of CI-AKI is discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7221.html" rel="external">"Prevention of contrast-associated acute kidney injury related to angiography"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/112897.html" rel="external">"Prevention of contrast-induced acute kidney injury associated with computed tomography"</a>.)</p><p></p><p class="headingAnchor" id="H130065707"><span class="h1">NATURAL HISTORY AND PROGNOSIS</span><span class="headingEndMark"> — </span>As noted above, patients with contrast-induced acute kidney injury (CI-AKI) usually have a mild reduction in glomerular filtration rate (GFR). In the majority of cases, the kidney function starts to improve within three to seven days, and the patient returns to, or close to, baseline estimated GFR (eGFR) [<a href="#rid8">8,39</a>]. In one study that included 21 patients with CI-AKI, 12 (57 percent) returned to baseline kidney function, and four additional patients (19 percent) had a partial recovery within five to seven days [<a href="#rid39">39</a>]. Five patients (24 percent) had persistent kidney dysfunction at the time of discharge.</p><p>Dialysis is rarely required for CI-AKI. In one study of over 1800 consecutive patients who underwent percutaneous interventions, the incidence of AKI that was severe enough to require dialysis was &lt;1 percent [<a href="#rid2">2</a>]. The risk may be higher among patients with severe, underlying chronic kidney disease (CKD) [<a href="#rid2">2,8,43</a>]. The indications for dialysis are the same in patients with CI-AKI as in other forms of AKI. (See  <a class="medical medical_review" href="/z/d/html/1927.html" rel="external">"Kidney replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose"</a>.)</p><p>The serum creatinine concentration is insensitive to modest reductions in GFR; residual kidney dysfunction may therefore persist, even if the creatinine has returned to baseline. Patients with underlying CKD have the highest risk of developing persistent kidney injury following an episode of AKI, and AKI in such patients increases the risk of CKD progression. This issue is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7225.html" rel="external">"Kidney and patient outcomes after acute kidney injury in adults", section on 'Degree of recovery'</a>.)</p><p>The development of contrast-associated AKI (CA-AKI) is associated with adverse short- and long-term outcomes. The 30-day, one-year, and five-year mortality risks are higher among patients who develop CA-AKI [<a href="#rid44">44-47</a>]. In one analysis of 9512 patients identified from randomized trials, the 30-day mortality rate was approximately 5 percent among patients who developed AKI following percutaneous coronary intervention compared with &lt;1 percent among those who did not [<a href="#rid45">45</a>]. Postcontrast AKI is also associated with greater rate of cardiovascular events, heart failure, and requirement for acute and maintenance dialysis [<a href="#rid48">48,49</a>].</p><p>However, it is possible that the association of CA-AKI with these adverse consequences is due to underlying comorbidities that contribute to both the AKI and to such outcomes [<a href="#rid50">50</a>].</p><p class="headingAnchor" id="H109658431"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Acute kidney injury (AKI) that occurs shortly after administration of iodinated contrast may or may not be causally related to contrast material. "Contrast-associated AKI (CA-AKI)" is a broad term that refers to AKI occurring shortly after administration of iodinated contrast and that may or may not be directly caused by the contrast material. "Contrast-induced AKI (CI-AKI)," previously called "contrast-induced nephropathy (CIN)," is a specific term that refers to the subset of CA-AKI that is judged, after a thorough clinical evaluation, to be causally linked to contrast material administration. The term CA-AKI applies to situations in which a detailed clinical evaluation for other potential AKI etiologies has not been performed or in which other causes of AKI cannot be reasonably excluded. CA-AKI should also be used to refer to increases in creatinine (or decreases in estimated glomerular filtration rate [eGFR]) after contrast exposure in research studies. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The major clinical manifestations of CI-AKI include (see <a class="local">'Clinical features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An increase in serum creatinine that is generally observed within 24 to 48 hours after the iodinated contrast exposure and that is usually mild.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most patients are nonoliguric. Oliguria may develop in patients with severe AKI and in patients with moderate to severe chronic kidney disease (CKD) at baseline.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The urinary sediment usually, but not always, shows classic findings of acute tubular necrosis (ATN), including muddy brown granular and epithelial cell casts and free renal tubular epithelial cells (<a class="graphic graphic_picture graphicRef56438" href="/z/d/graphic/56438.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef86348" href="/z/d/graphic/86348.html" rel="external">picture 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with suspected CI-AKI should undergo a focused history and physical exam and have a microscopic examination of the urinary sediment to identify findings that suggest an alternative etiology. Patients with oliguria and patients with severe AKI (who may require kidney replacement therapy) may be more likely to have an alternate etiology of AKI. A kidney ultrasound is not typically required, although it may be obtained to exclude other causes of AKI among patients with risk factors for urinary tract obstruction who do not follow a classic clinical course of CI-AKI, or if the diagnosis of CI-AKI is questionable (eg, oliguria, severe AKI). Protein excretion in patients with CI-AKI is typically absent or mild (unless the patient had proteinuric CKD at baseline). However, the presence of albuminuria (detected by a qualitative dipstick or by an albumin-to-creatinine ratio) does not exclude CI-AKI. (See <a class="local">'Evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CI-AKI is a clinical diagnosis. A clinical diagnosis of CI-AKI is made based upon the following features (see <a class="local">'Diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The characteristic rise in serum creatinine concentration beginning within the first 24 to 48 hours after contrast exposure</p><p class="bulletIndent2"><span class="glyph">•</span>In the judgment of the clinician, reasonable exclusion of other causes of AKI</p><p></p><p class="bulletIndent1">A kidney biopsy is generally not helpful for the diagnosis of CI-AKI, since the lesions of ATN are focal and nonspecific and because CI-AKI is generally short lived. However, as with the ultrasound, a biopsy may rarely be required to exclude other causes of AKI among patients who do not follow a classic clinical course or in whom the diagnosis of CI-AKI is uncertain.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The differential diagnosis includes, but is not limited to, renal atheroemboli (in setting of intra-arterial contrast administration), ischemic ATN, acute interstitial nephritis, and prerenal changes caused by the addition of or dose adjustments in diuretics and angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) in the postcontrast period. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As with most other etiologies of AKI, the management of patients with CI-AKI is supportive and includes elimination and avoidance of other potential kidney insults, hemodynamic and electrolyte assessment and management, appropriate dose adjustment of medications for the reduction in GFR, and, among those with severely decreased kidney function, monitoring for uremic signs and symptoms. An overview of the management of AKI is presented separately. (See <a class="local">'Management'</a> above and  <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">"Overview of the management of acute kidney injury (AKI) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with CI-AKI usually have a mild reduction in GFR that, in the majority of cases, starts to improve within three to seven days. Most patients return to, or close to, their baseline estimated GFR. Dialysis is rarely required for CI-AKI. (See <a class="local">'Natural history and prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Parfrey PS, Griffiths SM, Barrett BJ, et al. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study. N Engl J Med 1989; 320:143.</a></li><li><a class="nounderline abstract_t">Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47:254.</a></li><li><a class="nounderline abstract_t">Davidson CJ, Hlatky M, Morris KG, et al. Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial. Ann Intern Med 1989; 110:119.</a></li><li><a class="nounderline abstract_t">Schwab SJ, Hlatky MA, Pieper KS, et al. Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320:149.</a></li><li><a class="nounderline abstract_t">Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649.</a></li><li><a class="nounderline abstract_t">Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: incidence and risk factors. AJR Am J Roentgenol 1991; 157:49.</a></li><li><a class="nounderline abstract_t">Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media. AJR Am J Roentgenol 1991; 157:59.</a></li><li><a class="nounderline abstract_t">Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.</a></li><li><a class="nounderline abstract_t">Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994; 5:125.</a></li><li><a class="nounderline abstract_t">Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998; 53:230.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Palevsky PM. Radiocontrast-induced acute renal failure. J Intensive Care Med 2005; 20:63.</a></li><li><a class="nounderline abstract_t">Davenport MS, Cohan RH, Khalatbari S, Ellis JH. The challenges in assessing contrast-induced nephropathy: where are we now? AJR Am J Roentgenol 2014; 202:784.</a></li><li><a class="nounderline abstract_t">Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 2006; 239:392.</a></li><li><a class="nounderline abstract_t">Davenport MS, Khalatbari S, Dillman JR, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material. Radiology 2013; 267:94.</a></li><li><a class="nounderline abstract_t">McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon? Radiology 2013; 267:106.</a></li><li><a class="nounderline abstract_t">Davenport MS, Khalatbari S, Cohan RH, et al. Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate. Radiology 2013; 268:719.</a></li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Carter RE, et al. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. Radiology 2014; 271:65.</a></li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. Radiology 2013; 267:119.</a></li><li><a class="nounderline abstract_t">Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe? Radiology 2010; 256:21.</a></li><li><a class="nounderline abstract_t">Newhouse JH, Kho D, Rao QA, Starren J. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 2008; 191:376.</a></li><li><a class="nounderline abstract_t">Katzberg RW, Barrett BJ. Risk of iodinated contrast material--induced nephropathy with intravenous administration. Radiology 2007; 243:622.</a></li><li><a class="nounderline abstract_t">Hinson JS, Ehmann MR, Fine DM, et al. Risk of Acute Kidney Injury After Intravenous Contrast Media Administration. Ann Emerg Med 2017; 69:577.</a></li><li><a class="nounderline abstract_t">McDonald JS, McDonald RJ, Williamson EE, et al. Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study. Intensive Care Med 2017; 43:774.</a></li><li><a class="nounderline abstract_t">Wilhelm-Leen E, Montez-Rath ME, Chertow G. Estimating the Risk of Radiocontrast-Associated Nephropathy. J Am Soc Nephrol 2017; 28:653.</a></li><li><a class="nounderline abstract_t">Davenport MS, Perazella MA, Yee J, et al. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020; 294:660.</a></li><li class="breakAll">American College of Radiology. Committee on Drugs and Contrast Media. ACR Manual on Contrast Media, Version 10.3. 2017. 2017. https://www.acr.org/Quality-Safety/Resources/Contrast-Manual (Accessed on July 10, 2017).</li><li><a class="nounderline abstract_t">Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant 2005; 20:1542.</a></li><li><a class="nounderline abstract_t">Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68:14.</a></li><li><a class="nounderline abstract_t">Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy. Nephrol Dial Transplant 2005; 20 Suppl 1:i6.</a></li><li><a class="nounderline abstract_t">Agmon Y, Peleg H, Greenfeld Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94:1069.</a></li><li><a class="nounderline abstract_t">Weisberg LS, Kurnik PB, Kurnik BR. Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction. Kidney Int 1992; 41:1408.</a></li><li><a class="nounderline abstract_t">Cantley LG, Spokes K, Clark B, et al. Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int 1993; 44:1217.</a></li><li><a class="nounderline abstract_t">Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology 1995; 195:17.</a></li><li><a class="nounderline abstract_t">Russo D, Minutolo R, Cianciaruso B, et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6:1451.</a></li><li><a class="nounderline abstract_t">Pflueger A, Larson TS, Nath KA, et al. Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc 2000; 75:1275.</a></li><li><a class="nounderline abstract_t">Rudnick MR, Goldfarb S. Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality. Rev Cardiovasc Med 2003; 4 Suppl 5:S28.</a></li><li><a class="nounderline abstract_t">Molitoris BA, Dahl R, Geerdes A. Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia. Am J Physiol 1992; 263:F488.</a></li><li><a class="nounderline abstract_t">Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980; 140:531.</a></li><li><a class="nounderline abstract_t">Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990; 150:1237.</a></li><li><a class="nounderline abstract_t">Morcos SK, el-Nahas AM, Brown P, Haylor J. Effect of iodinated water soluble contrast media on urinary protein assays. BMJ 1992; 305:29.</a></li><li><a class="nounderline abstract_t">Wang C, Ma S, Deng B, et al. The predictive value of the product of contrast medium volume and urinary albumin/creatinine ratio in contrast-induced acute kidney injury. Ren Fail 2017; 39:555.</a></li><li><a class="nounderline abstract_t">McDonald JS, Steckler EM, McDonald RJ, et al. Bilateral Sustained Nephrograms After Parenteral Administration of Iodinated Contrast Material: A Potential Biomarker for Acute Kidney Injury, Dialysis, and Mortality. Mayo Clin Proc 2018; 93:867.</a></li><li><a class="nounderline abstract_t">Solomon RJ, Mehran R, Natarajan MK, et al. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009; 4:1162.</a></li><li><a class="nounderline abstract_t">Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259.</a></li><li><a class="nounderline abstract_t">Giacoppo D, Madhavan MV, Baber U, et al. Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials. Circ Cardiovasc Interv 2015; 8:e002475.</a></li><li><a class="nounderline abstract_t">From AM, Bartholmai BJ, Williams AW, et al. Mortality associated with nephropathy after radiographic contrast exposure. Mayo Clin Proc 2008; 83:1095.</a></li><li><a class="nounderline abstract_t">Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006; 17:2871.</a></li><li><a class="nounderline abstract_t">Chalikias G, Drosos I, Tziakas DN. Contrast-Induced Acute Kidney Injury: An Update. Cardiovasc Drugs Ther 2016; 30:215.</a></li><li><a class="nounderline abstract_t">Sato A, Aonuma K, Watanabe M, et al. Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: From the CINC-J study. Int J Cardiol 2017; 227:424.</a></li><li><a class="nounderline abstract_t">Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? Clin J Am Soc Nephrol 2008; 3:263.</a></li></ol></div><div id="topicVersionRevision">Topic 7241 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643041" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7731155" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2909204" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Cardiovascular and renal toxicity of a nonionic radiographic contrast agent after cardiac catheterization. A prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643042" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2729314" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dosing of contrast material to prevent contrast nephropathy in patients with renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2048539" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Radiocontrast-associated renal dysfunction: incidence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2048540" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Radiocontrast-associated renal dysfunction: a comparison of lower-osmolality and conventional high-osmolality contrast media.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7942832" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7993992" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Contrast nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453025" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contrast-medium-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855219" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Radiocontrast-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24660707" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The challenges in assessing contrast-induced nephropathy: where are we now?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16543592" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360737" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360742" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravenous contrast material-induced nephropathy: causal or coincident phenomenon?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23579046" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Contrast material-induced nephrotoxicity and intravenous low-osmolality iodinated contrast material: risk stratification by using estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24475854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23319662" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20574082" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intravenous contrast medium-induced nephrotoxicity: is the medical risk really as great as we have come to believe?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18647905" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17446526" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Risk of iodinated contrast material--induced nephropathy with intravenous administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28131489" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Risk of Acute Kidney Injury After Intravenous Contrast Media Administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28213620" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Post-contrast acute kidney injury in intensive care unit patients: a propensity score-adjusted study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27688297" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Estimating the Risk of Radiocontrast-Associated Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31961246" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31961246" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033768" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15954892" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Pathophysiology of contrast medium-induced nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705946" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Regional alterations in renal haemodynamics and oxygenation: a role in contrast medium-induced nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8083347" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1614056" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Radiocontrast-induced nephropathy in humans: role of renal vasoconstriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8301922" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7892462" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nephrotoxicity from contrast media: attenuation with theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589322" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11126837" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14668707" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pathogenesis of contrast-induced nephropathy: experimental and clinical observations with an emphasis on the role of osmolality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1329535" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cytoskeleton disruption and apical redistribution of proximal tubule Na(+)-K(+)-ATPase during ischemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7362385" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Low fractional excretion of sodium with contrast media-induced acute renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2353856" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1638196" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effect of iodinated water soluble contrast media on urinary protein assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28726528" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The predictive value of the product of contrast medium volume and urinary albumin/creatinine ratio in contrast-induced acute kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29976375" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Bilateral Sustained Nephrograms After Parenteral Administration of Iodinated Contrast Material: A Potential Biomarker for Acute Kidney Injury, Dialysis, and Mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19556381" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Contrast-induced nephropathy and long-term adverse events: cause and effect?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010907" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26198286" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes: Pooled Analysis From the HORIZONS-AMI and ACUITY Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18828968" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mortality associated with nephropathy after radiographic contrast exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16928802" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26780748" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Contrast-Induced Acute Kidney Injury: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838134" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Association of contrast-induced nephropathy with risk of adverse clinical outcomes in patients with cardiac catheterization: From the CINC-J study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18178787" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Contrast-induced nephropathy: what are the true clinical consequences?</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
